Cytogen’s new investors
Executive Summary
Lilly purchases 135,881 shares of common stock in the monoclonal antibody R&D company at a 25% premium to the market under an April agreement that grants Lilly a non-exclusive worldwide license to development and market certain cancer products using Cytogen technology. In addition, Italian drug firm Bracco Chimica purchases 250,000 Cytogen shares at $8 per share as part of a September R&D agreement covering magnetic resonance imaging enhancement agents.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.